CDSCO Tightens Drug Quality Checks, Requires Faulty Batch Recalls
In a significant move to ensure the safety and efficacy of drugs available in the Indian market, the Central Drugs Standard Control Organisation (CDSCO) has tightened its drug quality checks under the Drug and Cosmetics Act, 1940. As part of this initiative, the CDSCO has started flagging substandard drugs online, and manufacturers are now required to recall faulty batches.
This development was confirmed by Union Minister Anupriya Patel in a reply to a question raised in the Rajya Sabha on April 1. The minister’s statement has sent a strong signal to the pharmaceutical industry, emphasizing the importance of ensuring the quality of drugs sold in the country.
The CDSCO’s decision to tighten drug quality checks is a welcome move, given the growing concerns about the quality of drugs available in the market. In recent years, there have been several instances of substandard and spurious drugs being detected, which has raised concerns about patient safety.
To ensure that the quality of drugs is maintained, the CDSCO has launched a new portal called SUGAM Labs. This portal automates testing and tracking of drugs, making it easier for regulators to monitor the quality of medicines. The portal also enables manufacturers to submit their test results and other relevant information, making it easier for regulators to track the quality of drugs.
The SUGAM Labs portal is a significant step forward in the CDSCO’s efforts to ensure drug quality. With this portal, the CDSCO can now track the quality of drugs in real-time, allowing it to take swift action if any substandard drugs are detected. The portal also enables manufacturers to identify and recall faulty batches quickly, reducing the risk of harm to patients.
The CDSCO’s decision to tighten drug quality checks is also expected to boost the reputation of the Indian pharmaceutical industry. India is a major player in the global pharmaceutical industry, and the country’s reputation as a reliable supplier of high-quality medicines is at stake.
The Indian pharmaceutical industry has been facing challenges in recent years, including concerns about the quality of drugs and the lack of transparency in manufacturing processes. The CDSCO’s decision to tighten drug quality checks is a welcome move, as it sends a strong signal to manufacturers about the importance of ensuring the quality of drugs.
The CDSCO’s efforts to tighten drug quality checks are also expected to benefit patients. With the CDSCO monitoring the quality of drugs more closely, patients can be assured that the medicines they are taking are safe and effective.
In conclusion, the CDSCO’s decision to tighten drug quality checks is a significant development for the Indian pharmaceutical industry. The SUGAM Labs portal is a welcome innovation, as it automates testing and tracking of drugs, making it easier for regulators to monitor the quality of medicines. The CDSCO’s efforts to tighten drug quality checks are expected to boost the reputation of the Indian pharmaceutical industry and benefit patients by ensuring that the medicines they are taking are safe and effective.
Source: https://www.healthcareradius.in/government-policy/drug-pharma-cdsco
